ArticleInterdisciplinary perspectives on infectious diseases2026
Epidemiological Profile of Uropathogenic Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Article in Interdisciplinary perspectives on infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Epidemiological Profile of Uropathogenic Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Interdisciplinary perspectives on infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) represents a major challenge for the management of urinary tract infections (UTIs), limiting therapeutic options and increasing the risk of treatment failure. This study aimed to characterize the epidemiological profile and antimicrobial resistance patterns of ESBL-producing uropathogenic Methods: A retrospective descriptive study was conducted in the bacteriology department of the Moulay Ismail Military Hospital in Meknes, Morocco, over a 2-year period (2021-2023). Data were extracted from archived urine cytobacteriological examinations. Bacterial identification was performed using chromogenic media and biochemical methods, while antimicrobial susceptibility testing was carried out using the disk diffusion method according to CA-SFM guidelines. ESBL production was detected using the double-disk synergy test. Results: Among 9867 urine samples analyzed, 1676 cases of UTIs were identified, corresponding to a prevalence of 17%. Enterobacteriaceae accounted for 56.8% of isolates, among which ESBL-producing strains represented the majority of multidrug-resistant bacteria. Conclusions: This study highlights the increasing burden of ESBL-producing Enterobacteriaceae in UTIs and the alarming levels of resistance to commonly used antibiotics. These findings underscore the need for continuous surveillance, rational antibiotic use, and strengthened antimicrobial stewardship programs to limit the spread of multidrug-resistant bacteria and preserve the effectiveness of available treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.